S&P upgrades Concentra rating to BB on lower leverage

S&P Global Ratings has boosted Concentra Group Holdings Parent Inc.'s credit rating to BB from BB-, recognizing the company's solid operating performance and reduced financial risk following its split from Select Medical. The agency also enhanced the senior secured term loan rating to BB+ from BB and upgraded unsecured notes to B+ from B, while maintaining recovery ratings at 2 and 6, respectively.

Concentra's leverage, as measured by S&P Global Ratings, dipped below 3.5x in the second quarter, a full two quarters ahead of earlier projections. The company's adjusted leverage stands at 3.3x for fiscal 2026 and is expected to decrease to 3x in fiscal 2027. Management has set a target net leverage of 2.5x, or 3x on an S&P Global Ratings-adjusted basis, including leases.

In 2025, Concentra generated roughly $250 million in annual free operating cash flow after investing about $320 million in acquisitions of Nova Medical Centers and Pivot Onsite Innovations. The company's rolling-12-month S&P Global Ratings-adjusted EBITDA has risen by over $100 million since fiscal 2024, fueled by a surge in workers' compensation visits, rate increases, staffing efficiencies, and cost controls.

Concentra commands around 25% of the occupational health market, with 64% of employer locations within 12 miles of a center and a presence in 85 of the 100 largest metropolitan statistical areas. The company maintains mid-20% range EBITDA margins, with most revenue coming from employers and workers' compensation programs, with less than 1% from government payers.

S&P Global Ratings has assigned a stable outlook, predicting Concentra will continue to keep leverage under the 3.5x threshold. However, potential downgrade risks include sustained leverage above 3.5x due to excessive M&A or shareholder returns, or business decline from competition, lower injury rates, economic downturns, or state rate reductions. This report was produced with AI assistance and reviewed by an editor.